Global Vaccine Adjuvants Market – Industry Trends and Forecast to 2030

Vaccine Adjuvants Market Analysis and Size

The global vaccine adjuvants market is expected to experience significant growth in the coming years. Factors such as the increasing prevalence of Infectious Disease, expanding vaccination programs, and advancements in adjuvant development are driving market expansion. Additionally, the growing focus on developing vaccines for emerging diseases and the need for improved vaccine efficacy and safety further contribute to market growth.                                

Data Bridge Market Research analyses that the global vaccine adjuvants market which was USD 1,350.6 million in 2022, would rocket up to USD 2,950.57 million by 2030, and is expected to undergo a CAGR of 13.37% during the forecast period. This indicates that the market value. “Infectious” is expected to dominate the disease type segment of the vaccine adjuvants market owing to the growing demand for vaccines for infectious diseases. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Vaccine Adjuvants Market Scope and Segmentation

Market Definition

Vaccine adjuvants are the compounds that are consumed to enhance the body’s immunogenic response against antigens.  The vaccine adjuvants are used for a wide range of applications.

Global Vaccine Adjuvants Market Dynamics

Drivers

• Increasing Global Disease Burden

The rising prevalence of infectious diseases and the emergence of new pathogens continue to pose significant healthcare challenges globally. This drives the demand for effective vaccines and, in turn, vaccine adjuvants. The need for improved vaccine efficacy and the ability to provide protection against a broader range of pathogens are driving the development and use of adjuvant vaccines.

• Expansion of Vaccination Programs

Governments and healthcare organizations worldwide are actively expanding vaccination programs to prevent the spread of infectious diseases. This includes routine immunization, national immunization campaigns, and vaccination initiatives in response to epidemics or pandemics. The demand for adjuvants arises from the need to enhance the immune response and improve the effectiveness of vaccines used in these programs.

• Growing Focus on Preventive Healthcare

There is an increasing emphasis on preventive healthcare measures, including vaccination, to reduce the burden of infectious diseases. The recognition of the cost-effectiveness and public health benefits of vaccines has led to a greater focus on immunization programs. Vaccine adjuvants play a crucial role in enhancing the efficacy of vaccines and achieving the desired immune response, thereby supporting the growth of the market.

• Growing Investment for Healthcare Facilities

Surging focus on improving the condition of healthcare facilities and improving the overall healthcare infrastructure is another important factor fostering the growth of the market. The rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

• Technological Advancements in Vaccine Manufacturing

The advancement of vaccine manufacturing technologies, such as cell culture-based and recombinant DNA technologies, has enabled the production of more complex and targeted vaccines. Adjuvants play a critical role in optimizing these advanced vaccine formulations and improving their immunogenicity. As the vaccine manufacturing landscape evolves, the demand for adjuvants that can complement and enhance these technologies is expected to increase.

• Advancements in Adjuvant Technologies

The field of adjuvant research and development is continuously advancing, leading to the discovery and development of new and improved adjuvant technologies. Novel adjuvants offer enhanced safety profiles, improved immune responses, and better compatibility with vaccine formulations. The development of innovative adjuvant platforms drives the market by enabling the creation of more effective and tailored vaccines.

Restraints

• Stringent Regulatory Requirements

Vaccine adjuvants are subject to rigorous regulatory scrutiny due to their direct involvement in the immune response and safety considerations. The regulatory approval process for adjuvant vaccines can be complex and time-consuming. Stringent regulatory requirements may pose challenges for companies developing and commercializing vaccine adjuvants, leading to delays in market entry and increased costs.

• Safety Concerns and Public Perception

Safety concerns surrounding adjuvant vaccines can impact market acceptance. Although adjuvants are generally considered safe, rare adverse events or public controversies related to vaccine safety can erode public trust and confidence in adjuvant vaccines. Communicating the safety profile and benefits of adjuvant vaccines effectively to the public is crucial for market adoption.

Challenges

• Regulatory Hurdles and Approval Processes

Vaccine adjuvants are subject to stringent regulatory requirements, and gaining regulatory approval can be a significant challenge. Adjuvants are considered an integral part of the vaccine formulation, and their safety, efficacy, and stability must be thoroughly evaluated. The regulatory process often involves extensive preclinical and clinical studies, which can be time-consuming and costly. Navigating the complex regulatory landscape and meeting the requirements pose challenges for companies developing and commercializing vaccine adjuvants.

• Cost and Affordability

Vaccine adjuvants can contribute to the overall cost of vaccine development and production. The cost-effectiveness of adjuvants, especially when combined with the cost of adjuvant vaccine production, can be a challenge. Balancing the need for improved vaccine efficacy and immune response with the cost implications is a critical consideration for both manufacturers and healthcare systems. Developing cost-effective adjuvants and optimizing manufacturing processes to reduce production costs are ongoing challenges in the market.

This vaccine adjuvants market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the vaccine adjuvants market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In April 2022, GSK and SK Bioscience submitted a biologics license application to the Korean Ministry of Food and Drug Safety (KMFDS) for their SKYCovione following positive Phase III clinical data. It is a recombinant protein-based COVID-19 vaccine candidate adjuvanted with GSK’s pandemic adjuvant
• In February 2022, Sanofi and GSK intended to submit data from their booster and Phase 3 efficacy trials as the basis for regulatory applications for a COVID-19 vaccine.

Global Vaccine Adjuvants Market Scope

The vaccine adjuvants market is segmented on the basis of product type, route of administration, disease type, application, application category, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Particulate adjuvants
• Adjuvant emulsions
• Pathogen components
• Combination adjuvants
• Liposome adjuvants
• Carbohydrate adjuvants
• Alum
• Others

Route of Administration

• Intramuscular route
• Subcutaneous route
• Intranasal route
• Oral route
• Intradermal route
• Others

Disease Type

• Infectious diseases
• Cancer
• Others

Application

• Research application
• Commercial application

Application Category

• Human vaccine adjuvants
• Veterinary vaccine adjuvants

End-User

• Pediatric
• Adults
• Others

Vaccine Adjuvants Market Regional Analysis/Insights

The vaccine adjuvants market is analysed and market size insights and trends are provided by country, product type, route of administration, disease type, application, application category, and end-user as referenced above.

The countries covered in the vaccine adjuvants market report are U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of the Middle East and Africa.

North America is expected to dominate the vaccine adjuvants market owing to the well-established veterinary healthcare infrastructure.   

Asia-Pacific is projected to score the highest growth rate and exhibit the highest CAGR for the forecast period. This is because of the rising expenditure to develop veterinary healthcare infrastructure and the increased focus of the government on immunization programs.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The vaccine adjuvants market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for the vaccine adjuvants market, impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the vaccine adjuvants market. The data is available for the historic period 2015-2020.

Competitive Landscape and Vaccine Adjuvants Market Share Analysis

The vaccine adjuvants market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the vaccine adjuvants market.

Some of the major players operating in the vaccine adjuvants market are:

• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Astrazeneca (U.K.)
• Abbott (U.S.)
• 3M (U.S.)
• Adjuvatis (France)
• Merck KGaA (Germany)
• Croda International Plc (U.K.)
• Novavax, Inc. (U.S.)
• InvivoGen (France)
• CSL Limited (Australia)
• SPI Pharma(U.S.)
• Phibro Animal Health Corporation. (U.S.)
• SEPPIC (France)
• Agenus Inc. (U.S.)
• OZ Biosciences (France)
• Kineta, Inc. (U.S.)
• vaxine (Australia)
• Astellas Pharma Inc. (Japan)
• CureVac AG (Germany)
• Bavarian Nordic (Denmark)

SKU-14379